ClinicalTrials.Veeva

Menu

Assessing the Right Heart Remodeling After Transcatheter Tricuspid Edge-to-edge Repair (HERITAGE)

I

Istituto Auxologico Italiano

Status

Enrolling

Conditions

Tricuspid Regurgitation

Treatments

Device: Tricuspid transcatheter edge-to-edge repair

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

In the recent years, secondary tricuspid regurgitation (STR) has gained interest due to its high prevalence and impact on outcomes. Transcatheter tricuspid valve replacement or repair represents novel and less invasive alternatives to surgery and has shown early promising results. Treatment options mimic surgical techniques such as leaflet approximation, direct annuloplasty, and heterotopic caval valve implantation, as well as not yet commercially available transcatheter TV replacement systems using orthotopic valve implantation. (5) Among leaflet approximation techniques, the Tricuspid transcatheter edge-to-edge repair (T-TEER) using the TriClip™ (Abbott Vascular, Santa Clara, CA, USA) or leaflet approximation with the PASCAL systems (Edwards Lifesciences, Irvine, CA, USA) are approved in Europe for minimally invasive TV repair.The purposes of the present study are: i. to use 3DE and CCT to evaluate the effect of T-TEER on the geometry and function of the right heart chambers in patients with STR; ii. to identify the predictors of procedural success potentially related to features of both right chambers geometry and TR jet; iii. to compare the accuracy of 3DE assessment of the right ventricle, the right atrium, and the tricuspid annulus, with the same parameters obtained by CCT, in the setting of T-TEER; and iv. to assess patients' outcome.

Enrollment

17 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age> 18 years
  • Severe STR, amenable to percutaneous treatment with T-TEER
  • Acceptance to be part of this study by signing the informed consent
  • Good enough acoustic window and ability to cooperate in order to obtain 3D echo data sets of cardiac structures with a minimum temporal resolution of 20 fps
  • Availability for clinical, CCT and, echocardiography follow-up visits

Exclusion criteria

  • Pregnancy
  • Severe chronic kidney disease (GFR <30 mL/min)
  • Hypersensitivity reactions to contrast media
  • Cardiovascular implantable electronic device-related (CIED) tricuspid regurgitation.
  • Bad acoustic window with inadequate echocardiographic images.

Trial contacts and locations

1

Loading...

Central trial contact

Luca Grappiolo

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems